Vergent Bioscience, a biotech company specializing in imaging agents, has raised $21.5 million in series B financing.
Vergent plans to use the funding to advance the development of the company's fluorescent tumor imaging agent VGT-309. Initially, VGT-309 will be used to illuminate lung cancer tumors, according to the Oct. 4 Vergent news release.
Orlando Health Ventures led the funding round. This funding round brings Vergent's total capital raised to $34 million.